Enquire Now

Technical Report on Gland Pharma by Shyam Advisory

December 27, 2021

Gland Pharma :-Established in Hyderabad, India in 1978, Gland Pharma has grown
over the years from a contract manufacturer of small volume liquid parenteral
products, to become one of the largest and fastest growing injectable-focused
companies, with a global footprint across 60 countries, including the United States,
Europe, Canada, Australia, India and other markets. We operate primarily under a
business to business (B2B) model and have an excellent track record in the
development, manufacturing and marketing of complex injectable. This presence
across the value chain has helped us witness exponential growth. We are promoted by
Shanghai Fosun Pharma, a global pharmaceutical major.

GLAND PHARMA 1 - Shyam Advisory
Technical View: The stock had a down trend breakout with strong bullish candle,
Structure look positive it is above to form round up structure , RSI divergence
indicate buying signal and MACD crossover is supporting trend, Classical
rounding pattern structure indicate positive move in near term.
Volume analysis: – Quantity traded in last session was 177571, where deliverable
quantity 68342 and deliverable quantity traded 38 %
Moving Averages: – Gland Pharma Ltd is trading higher than 5 day, 20 day, 50 day,
100 day and 200 day moving averages
5 Day 3,673.75 50 Day 3,618.37 200 Day 3,388.08
20 Day 3,603.74 100 Day 3,780.39
Date:- 27/12/2021
Shareholding pattern:-

GLAND PHARMA 2 - Shyam Advisory
Promoters holding 58.02%, The Promoter holdings have decrease by 0.12% .
However, the number of shares held by the Promoters has remained constant, No
change in Promoter pledged shares
Key Statistics
 Market Cap ₹63,977Cr.
 Current Price ₹3,894
 High / Low ₹4,350/2,051
 Stock P/E 57.3
 Book Value ₹401
 Dividend Yield 0.00%
 ROCE 28.0%
 ROE 20.9%
 Face Value ₹1.00
 Sales ₹3,982Cr.
 Profit after tax ₹1,117Cr.
 Mar Cap ₹63,977Cr.
 Pledged percentage 0.00%
 Promoter holding 58.0%
 Debt ₹4.79Cr.
 Return on equity 20.9%
 Debt to equity 0.00
 Price to book value 9.70
 Price to Earning 57.3